Chemotherapy News and Research

Latest Chemotherapy News and Research

Oregano ingredient could treat prostate cancer

Oregano, the common pizza and pasta seasoning herb, has long been known to possess a variety of beneficial health effects, but a new study by researchers at Long Island University (LIU) indicates that an ingredient of this spice could potentially be used to treat prostate cancer, the second leading cause of cancer death in American men.

25 Apr 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

IGF1R-blocking drugs can treat children with Wilms' tumour

An experimental drug that blocks an essential cell protein could be used to treat Wilms' tumour, a childhood cancer that affects the kidneys.

24 Apr 2012

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.

23 Apr 2012

Delcath closes $20M credit facility

Delcath Systems, Inc. today announced it has closed a $20 million working capital line of credit revolver with Silicon Valley Bank, a leading provider of banking services in the life sciences. The credit facility is available for general corporate purposes supporting the overall growth and development of the Company.

23 Apr 2012

VeriStrat test may be useful for NSCLC clinical decision-making

Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib.

21 Apr 2012

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012.

21 Apr 2012

Chemotherapy, radiation affect cognitive function of women with breast cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and University of Kentucky have found that breast cancer survivors who have had chemotherapy, radiation or both do not perform as well on some cognitive tests as women who have not had cancer.

21 Apr 2012

Possibility to render cancer tumours harmless without affecting other cells

New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study was carried out at Lund University in Sweden.

20 Apr 2012

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Something in the world of medicine is seriously amiss. Unhappy patients gripe about their doctors' brusque manner and give them bad marks on surveys and consumer websites like HealthGrades and Angie's List. They tell tales of being rushed out of the office by harried doctors who miss crucial diagnoses, never look up from their computers during an exam, make errors in prescriptions, and just plain don't listen to their patients. ... And things don't seem much better from the other side of the stethoscope.

20 Apr 2012

Study evaluates factors associated with breast cancer worry

"Cancer worry" is the fear that cancer will return, said researchers at Moffitt Cancer Center who studied cancer worry among breast cancer survivors and published their findings in Psycho-Oncology. They found that even three years after successful treatment, two-thirds of the 202 breast cancer survivors who participated in their study said they had "a moderate level of worry."

20 Apr 2012

Breast cancer treatment and classification revolutionized in landmark study

Breast cancer treatment could be revolutionized with patients offered more accurate diagnoses and better-targeted treatments after a study in which scientists genetically charted the disease. The research found that rather than being a single disease, breast cancer can be classified into 10 distinct types. It also identified several new genes that determine the aggressiveness of the cancer.

19 Apr 2012

Inform Genomics completes first phase in oral mucositis risk prediction study

Inform Genomics, Inc., a private company focused on developing novel platforms of personalized medicine products for cancer supportive care and inflammatory diseases, today announced the completion of the first phase of product development to predict a patient's risk of developing oral mucositis after receiving high dose chemotherapy prior to hematopoietic stem cell transplant.

19 Apr 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

NSCLC patients with EGFR mutations benefit from erlotinib-first regimen

Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

Magnetic nanochain detonates chemo barrage inside tumors

Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at Case Western Reserve University report.

19 Apr 2012

Study: 1 in 5 cancer patients may experience ‘breakdowns’ in their care

Cancer care is increasingly complex, and as many as one in five cancer patients may experience "breakdowns" in their care, according to a new study in the Journal of Clinical Oncology. Such breakdowns include communication problems between patients and their care providers, as well as more traditional medical errors; both types of problems can create significant harms. In the study, communication problems outnumbered problems with medical care.

19 Apr 2012

New genetic signature may predict NSCLC patients at risk of relapse

A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.

19 Apr 2012

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA.

18 Apr 2012